Prostate biopsy is a critical method for distinguishing between benign and malignant prostate tumors.As the population ages and the incidence of cardiovascular diseases gradually increases,patients scheduled for pros-tate biopsy often receive antithrombotic treatment due to concurrent cardiovascular conditions.During the periopera-tive period,the continuation of antithrombotic medications raises the risk of bleeding,whereas their discontinuation may lead to thrombosis and potentially exacerbate cardiovascular diseases.The establishment of standardized manage-ment protocols for antithrombotic drugs in these patients is an urgent issue that requires resolution.The consensus is reached through multidisciplinary discussions among relevant experts,combined with the latest domestic and interna-tional literature and guideline evidence.The objective is to clarify the timing of prostate biopsy,balance the risks of perioperative bleeding and thrombosis,formulate standardized management strategies for antithrombotic medica-tions,and develop clinical management plans for postoperative bleeding,thereby providing a foundation and guidance for clinical diagnosis and treatment.
维普
万方数据